{
  "disease_name": "Mucopolysaccharidosis type 1",
  "orpha_code": "579",
  "drugs": [
    {
      "name": "ALDURAZYME",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/131351?name=579&mode=orpha&region=",
      "regulatory_id": "131351",
      "orpha_substance_code": "ORPHA:579",
      "details": [
        "ALDURAZYME(Tradename                        - 10/06/2003)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "ALDURAZYME(Tradename                        - 10/06/2003)",
        "(Tradename                        - 10/06/2003)",
        "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/42576?name=579&mode=orpha&region=&status=all",
          "text": "ALDURAZYME",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/579",
          "text": "ORPHA:579 Mucopolysaccharidosis type 1",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/131351?name=579&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Alpha-L-iduronidase fused to Fab fragment of a humanised monoclonal antibody targeting human transferrin receptor",
      "substance_url": "/en/drug/substance/627351?name=579&mode=orpha&region=&status=all",
      "substance_id": "627351",
      "regulatory_url": "/en/drug/regulatory/627353?name=579&mode=orpha&region=",
      "regulatory_id": "627353",
      "orpha_substance_code": "ORPHA:579",
      "details": [
        "Alpha-L-iduronidase fused to Fab fragment of a humanised monoclonal antibody targeting human transferrin receptor(Medicinal product                        - 26/03/2021)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "Alpha-L-iduronidase fused to Fab fragment of a humanised monoclonal antibody targeting human transferrin receptor(Medicinal product                        - 26/03/2021)",
        "(Medicinal product                        - 26/03/2021)",
        "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/627351?name=579&mode=orpha&region=&status=all",
          "text": "Alpha-L-iduronidase fused to Fab fragment of a humanised monoclonal antibody targeting human transferrin receptor",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/579",
          "text": "ORPHA:579 Mucopolysaccharidosis type 1",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/627353?name=579&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA",
      "substance_url": "/en/drug/substance/531808?name=579&mode=orpha&region=&status=all",
      "substance_id": "531808",
      "regulatory_url": "/en/drug/regulatory/531809?name=579&mode=orpha&region=",
      "regulatory_id": "531809",
      "orpha_substance_code": "ORPHA:579",
      "details": [
        "autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA(Medicinal product                        - 26/10/2018)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA(Medicinal product                        - 26/10/2018)",
        "(Medicinal product                        - 26/10/2018)",
        "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/531808?name=579&mode=orpha&region=&status=all",
          "text": "autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/579",
          "text": "ORPHA:579 Mucopolysaccharidosis type 1",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/531809?name=579&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Recombinant adeno-associated viral vector serotype 9 containing human iduronidase gene",
      "substance_url": "/en/drug/substance/520947?name=579&mode=orpha&region=&status=all",
      "substance_id": "520947",
      "regulatory_url": "/en/drug/regulatory/520948?name=579&mode=orpha&region=",
      "regulatory_id": "520948",
      "orpha_substance_code": "ORPHA:579",
      "details": [
        "Recombinant adeno-associated viral vector serotype 9 containing human iduronidase gene(Medicinal product                        - 27/06/2018)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "Recombinant adeno-associated viral vector serotype 9 containing human iduronidase gene(Medicinal product                        - 27/06/2018)",
        "(Medicinal product                        - 27/06/2018)",
        "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/520947?name=579&mode=orpha&region=&status=all",
          "text": "Recombinant adeno-associated viral vector serotype 9 containing human iduronidase gene",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/579",
          "text": "ORPHA:579 Mucopolysaccharidosis type 1",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/520948?name=579&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate",
      "substance_url": "/en/drug/substance/480798?name=579&mode=orpha&region=&status=all",
      "substance_id": "480798",
      "regulatory_url": "/en/drug/regulatory/480800?name=579&mode=orpha&region=",
      "regulatory_id": "480800",
      "orpha_substance_code": "ORPHA:579",
      "details": [
        "6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate(Medicinal product                        - 22/09/2016)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate(Medicinal product                        - 22/09/2016)",
        "(Medicinal product                        - 22/09/2016)",
        "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/480798?name=579&mode=orpha&region=&status=all",
          "text": "6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/579",
          "text": "ORPHA:579 Mucopolysaccharidosis type 1",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/480800?name=579&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Pentosan polysulfate sodium",
      "substance_url": "/en/drug/substance/412265?name=579&mode=orpha&region=&status=all",
      "substance_id": "412265",
      "regulatory_url": "/en/drug/regulatory/637758?name=579&mode=orpha&region=",
      "regulatory_id": "637758",
      "orpha_substance_code": "ORPHA:579",
      "details": [
        "Pentosan polysulfate sodium(Medicinal product                        - 19/11/2014)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "Pentosan polysulfate sodium(Medicinal product                        - 19/11/2014)",
        "(Medicinal product                        - 19/11/2014)",
        "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/412265?name=579&mode=orpha&region=&status=all",
          "text": "Pentosan polysulfate sodium",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/579",
          "text": "ORPHA:579 Mucopolysaccharidosis type 1",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/637758?name=579&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Allogeneic retinal pigment epithelial cells genetically modified with a non-viral vector to express human alpha-L-iduronidase",
      "substance_url": "/en/drug/substance/627993?name=579&mode=orpha&region=&status=all",
      "substance_id": "627993",
      "regulatory_url": "/en/drug/regulatory/627994?name=579&mode=orpha&region=",
      "regulatory_id": "627994",
      "orpha_substance_code": "ORPHA:579",
      "details": [
        "Allogeneic retinal pigment epithelial cells genetically modified with a non-viral vector to express human alpha-L-iduronidase(Medicinal product                        - 15/10/2021)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "Allogeneic retinal pigment epithelial cells genetically modified with a non-viral vector to express human alpha-L-iduronidase(Medicinal product                        - 15/10/2021)",
        "(Medicinal product                        - 15/10/2021)",
        "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/627993?name=579&mode=orpha&region=&status=all",
          "text": "Allogeneic retinal pigment epithelial cells genetically modified with a non-viral vector to express human alpha-L-iduronidase",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/579",
          "text": "ORPHA:579 Mucopolysaccharidosis type 1",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/627994?name=579&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human alpha L-iduronidase gene",
      "substance_url": "/en/drug/substance/510771?name=579&mode=orpha&region=&status=all",
      "substance_id": "510771",
      "regulatory_url": "/en/drug/regulatory/510772?name=579&mode=orpha&region=",
      "regulatory_id": "510772",
      "orpha_substance_code": "ORPHA:579",
      "details": [
        "Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human alpha L-iduronidase gene(Medicinal product                        - 17/01/2018)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human alpha L-iduronidase gene(Medicinal product                        - 17/01/2018)",
        "(Medicinal product                        - 17/01/2018)",
        "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/510771?name=579&mode=orpha&region=&status=all",
          "text": "Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human alpha L-iduronidase gene",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/579",
          "text": "ORPHA:579 Mucopolysaccharidosis type 1",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/510772?name=579&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Ataluren",
      "substance_url": "/en/drug/substance/82038?name=579&mode=orpha&region=&status=all",
      "substance_id": "82038",
      "regulatory_url": "/en/drug/regulatory/625924?name=579&mode=orpha&region=",
      "regulatory_id": "625924",
      "orpha_substance_code": "ORPHA:579",
      "details": [
        "Ataluren(Medicinal product                        - 19/11/2014)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "Ataluren(Medicinal product                        - 19/11/2014)",
        "(Medicinal product                        - 19/11/2014)",
        "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/82038?name=579&mode=orpha&region=&status=all",
          "text": "Ataluren",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/579",
          "text": "ORPHA:579 Mucopolysaccharidosis type 1",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/625924?name=579&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Recombinant human insulin receptor monoclonal antibody-fused-alpha-L-iduronidase",
      "substance_url": "/en/drug/substance/410400?name=579&mode=orpha&region=&status=all",
      "substance_id": "410400",
      "regulatory_url": "/en/drug/regulatory/415075?name=579&mode=orpha&region=",
      "regulatory_id": "415075",
      "orpha_substance_code": "ORPHA:579",
      "details": [
        "Recombinant human insulin receptor monoclonal antibody-fused-alpha-L-iduronidase(Medicinal product                        - 15/10/2014)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "Recombinant human insulin receptor monoclonal antibody-fused-alpha-L-iduronidase(Medicinal product                        - 15/10/2014)",
        "(Medicinal product                        - 15/10/2014)",
        "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/410400?name=579&mode=orpha&region=&status=all",
          "text": "Recombinant human insulin receptor monoclonal antibody-fused-alpha-L-iduronidase",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/579",
          "text": "ORPHA:579 Mucopolysaccharidosis type 1",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/415075?name=579&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Laronidase",
      "substance_url": "/en/drug/substance/42577?name=579&mode=orpha&region=&status=all",
      "substance_id": "42577",
      "regulatory_url": "/en/drug/regulatory/133654?name=579&mode=orpha&region=",
      "regulatory_id": "133654",
      "orpha_substance_code": "ORPHA:579",
      "details": [
        "Laronidase(Medicinal product                        - 14/02/2001)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "Laronidase(Medicinal product                        - 14/02/2001)",
        "(Medicinal product                        - 14/02/2001)",
        "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/42577?name=579&mode=orpha&region=&status=all",
          "text": "Laronidase",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/579",
          "text": "ORPHA:579 Mucopolysaccharidosis type 1",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/133654?name=579&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "ALDURAZYME",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/131132?name=579&mode=orpha&region=",
      "regulatory_id": "131132",
      "orpha_substance_code": "ORPHA:579",
      "details": [
        "ALDURAZYME(Tradename                        - 30/04/2003)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "ALDURAZYME(Tradename                        - 30/04/2003)",
        "(Tradename                        - 30/04/2003)",
        "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/42576?name=579&mode=orpha&region=&status=all",
          "text": "ALDURAZYME",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/579",
          "text": "ORPHA:579 Mucopolysaccharidosis type 1",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/131132?name=579&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Self-complementary adeno-associated virus serotype 9 vector harboring a miniaturized codon-optimized human IDUA gene",
      "substance_url": "/en/drug/substance/673959?name=579&mode=orpha&region=&status=all",
      "substance_id": "673959",
      "regulatory_url": "/en/drug/regulatory/674191?name=579&mode=orpha&region=",
      "regulatory_id": "674191",
      "orpha_substance_code": "ORPHA:579",
      "details": [
        "Self-complementary adeno-associated virus serotype 9 vector harboring a miniaturized codon-optimized human IDUA gene(Medicinal product                        - 08/04/2024)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "Self-complementary adeno-associated virus serotype 9 vector harboring a miniaturized codon-optimized human IDUA gene(Medicinal product                        - 08/04/2024)",
        "(Medicinal product                        - 08/04/2024)",
        "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/673959?name=579&mode=orpha&region=&status=all",
          "text": "Self-complementary adeno-associated virus serotype 9 vector harboring a miniaturized codon-optimized human IDUA gene",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/579",
          "text": "ORPHA:579 Mucopolysaccharidosis type 1",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/674191?name=579&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Alpha-L-iduronidase (IDUA) - ricin transport subunit B (RTB) lectin protein fusion",
      "substance_url": "/en/drug/substance/643872?name=579&mode=orpha&region=&status=all",
      "substance_id": "643872",
      "regulatory_url": "/en/drug/regulatory/643873?name=579&mode=orpha&region=",
      "regulatory_id": "643873",
      "orpha_substance_code": "ORPHA:579",
      "details": [
        "Alpha-L-iduronidase (IDUA) - ricin transport subunit B (RTB) lectin protein fusion(Medicinal product                        - 01/07/2022)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "Alpha-L-iduronidase (IDUA) - ricin transport subunit B (RTB) lectin protein fusion(Medicinal product                        - 01/07/2022)",
        "(Medicinal product                        - 01/07/2022)",
        "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/643872?name=579&mode=orpha&region=&status=all",
          "text": "Alpha-L-iduronidase (IDUA) - ricin transport subunit B (RTB) lectin protein fusion",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/579",
          "text": "ORPHA:579 Mucopolysaccharidosis type 1",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/643873?name=579&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Laronidase",
      "substance_url": "/en/drug/substance/42577?name=579&mode=orpha&region=&status=all",
      "substance_id": "42577",
      "regulatory_url": "/en/drug/regulatory/136698?name=579&mode=orpha&region=",
      "regulatory_id": "136698",
      "orpha_substance_code": "ORPHA:579",
      "details": [
        "Laronidase(Medicinal product                        - 24/09/1997)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "Laronidase(Medicinal product                        - 24/09/1997)",
        "(Medicinal product                        - 24/09/1997)",
        "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/42577?name=579&mode=orpha&region=&status=all",
          "text": "Laronidase",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/579",
          "text": "ORPHA:579 Mucopolysaccharidosis type 1",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/136698?name=579&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "PLERIXAFOR ACCORD",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/642317?name=579&mode=orpha&region=",
      "regulatory_id": "642317",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
        "(Tradename                        - 16/12/2022)",
        "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/642316?name=579&mode=orpha&region=&status=all",
          "text": "PLERIXAFOR ACCORD",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/29073",
          "text": "ORPHA:29073 Multiple myeloma",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/223735",
          "text": "ORPHA:223735 Lymphoma",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/642317?name=579&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Thiotepa Riemser",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/610636?name=579&mode=orpha&region=",
      "regulatory_id": "610636",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Thiotepa Riemser(Tradename                        - 26/03/2021)",
        "(Tradename                        - 26/03/2021)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/610616?name=579&mode=orpha&region=&status=all",
          "text": "Thiotepa Riemser",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/610636?name=579&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "motixafortide",
      "substance_url": "/en/drug/substance/588874?name=579&mode=orpha&region=&status=all",
      "substance_id": "588874",
      "regulatory_url": "/en/drug/regulatory/661036?name=579&mode=orpha&region=",
      "regulatory_id": "661036",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "motixafortide(Medicinal product                        - 12/01/2024)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "motixafortide(Medicinal product                        - 12/01/2024)",
        "(Medicinal product                        - 12/01/2024)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/588874?name=579&mode=orpha&region=&status=all",
          "text": "motixafortide",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/661036?name=579&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate",
      "substance_url": "/en/drug/substance/589233?name=579&mode=orpha&region=&status=all",
      "substance_id": "589233",
      "regulatory_url": "/en/drug/regulatory/589234?name=579&mode=orpha&region=",
      "regulatory_id": "589234",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate(Medicinal product                        - 20/04/2020)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate(Medicinal product                        - 20/04/2020)",
        "(Medicinal product                        - 20/04/2020)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/589233?name=579&mode=orpha&region=&status=all",
          "text": "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/589234?name=579&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus",
      "substance_url": "/en/drug/substance/589056?name=579&mode=orpha&region=&status=all",
      "substance_id": "589056",
      "regulatory_url": "/en/drug/regulatory/589057?name=579&mode=orpha&region=",
      "regulatory_id": "589057",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus(Medicinal product                        - 24/03/2020)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus(Medicinal product                        - 24/03/2020)",
        "(Medicinal product                        - 24/03/2020)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/589056?name=579&mode=orpha&region=&status=all",
          "text": "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/589057?name=579&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Burixafor",
      "substance_url": "/en/drug/substance/689505?name=579&mode=orpha&region=&status=all",
      "substance_id": "689505",
      "regulatory_url": "/en/drug/regulatory/689915?name=579&mode=orpha&region=",
      "regulatory_id": "689915",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "Burixafor(Medicinal product                        - 22/10/2024)Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "Burixafor(Medicinal product                        - 22/10/2024)",
        "(Medicinal product                        - 22/10/2024)",
        "Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/689505?name=579&mode=orpha&region=&status=all",
          "text": "Burixafor",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/689915?name=579&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Besilesomab",
      "substance_url": "/en/drug/substance/571152?name=579&mode=orpha&region=&status=all",
      "substance_id": "571152",
      "regulatory_url": "/en/drug/regulatory/641081?name=579&mode=orpha&region=",
      "regulatory_id": "641081",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Besilesomab(Medicinal product                        - 28/03/2022)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Besilesomab(Medicinal product                        - 28/03/2022)",
        "(Medicinal product                        - 28/03/2022)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/571152?name=579&mode=orpha&region=&status=all",
          "text": "Besilesomab",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/641081?name=579&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Besilesomab",
      "substance_url": "/en/drug/substance/571152?name=579&mode=orpha&region=&status=all",
      "substance_id": "571152",
      "regulatory_url": "/en/drug/regulatory/641075?name=579&mode=orpha&region=",
      "regulatory_id": "641075",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Besilesomab(Medicinal product                        - 28/03/2022)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Besilesomab(Medicinal product                        - 28/03/2022)",
        "(Medicinal product                        - 28/03/2022)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/571152?name=579&mode=orpha&region=&status=all",
          "text": "Besilesomab",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/641075?name=579&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Treosulfan",
      "substance_url": "/en/drug/substance/90799?name=579&mode=orpha&region=&status=all",
      "substance_id": "90799",
      "regulatory_url": "/en/drug/regulatory/136690?name=579&mode=orpha&region=",
      "regulatory_id": "136690",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "Treosulfan(Medicinal product                        - 08/04/2015)Disease(s) concernedORPHA:213500 Rare ovarian cancerORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "Treosulfan(Medicinal product                        - 08/04/2015)",
        "(Medicinal product                        - 08/04/2015)",
        "Disease(s) concernedORPHA:213500 Rare ovarian cancerORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/90799?name=579&mode=orpha&region=&status=all",
          "text": "Treosulfan",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/213500",
          "text": "ORPHA:213500 Rare ovarian cancer",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/136690?name=579&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "busulfan",
      "substance_url": "/en/drug/substance/46335?name=579&mode=orpha&region=&status=all",
      "substance_id": "46335",
      "regulatory_url": "/en/drug/regulatory/131973?name=579&mode=orpha&region=",
      "regulatory_id": "131973",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "busulfan(Medicinal product                        - 21/04/1994)Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "busulfan(Medicinal product                        - 21/04/1994)",
        "(Medicinal product                        - 21/04/1994)",
        "Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/46335?name=579&mode=orpha&region=&status=all",
          "text": "busulfan",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/131973?name=579&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    }
  ],
  "processing_timestamp": "2025-07-07T05:59:52.616749",
  "run_number": 1,
  "total_drugs_found": 25,
  "search_url": "https://www.orpha.net/en/drug?diseaseName=Mucopolysaccharidosis+type+1&orphaCode=579&name=579&region=&mode=orpha&status=all",
  "search_params": {
    "diseaseName": "Mucopolysaccharidosis type 1",
    "orphaCode": "579",
    "name": "579",
    "region": "",
    "mode": "orpha",
    "status": "all"
  }
}